Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine.
about
Structural and Biochemical Characterization of the Vaccinia Virus Envelope Protein D8 and Its Recognition by the Antibody LA5Potent Neutralization of Vaccinia Virus by Divergent Murine Antibodies Targeting a Common Site of Vulnerability in L1 ProteinIdentification of the feline humoral immune response to Bartonella henselae infection by protein microarrayProteomic basis of the antibody response to monkeypox virus infection examined in cynomolgus macaques and a comparison to human smallpox vaccination.Phenotypic and functional characterization of human memory T cell responses to Burkholderia pseudomallei.Human antibody responses to the polyclonal Dryvax vaccine for smallpox prevention can be distinguished from responses to the monoclonal replacement vaccine ACAM2000.Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors.Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model.Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activityGM-CSF production allows the identification of immunoprevalent antigens recognized by human CD4+ T cells following smallpox vaccination.The neutralizing antibody response to the vaccinia virus A28 protein is specifically enhanced by its association with the H2 proteinDefinition of epitopes and antigens recognized by vaccinia specific immune responses: their conservation in variola virus sequences, and use as a model system to study complex pathogensPlasmodium immunomics.Protection of rabbits and immunodeficient mice against lethal poxvirus infections by human monoclonal antibodies.Profiling humoral immune responses to P. falciparum infection with protein microarraysCapturing the natural diversity of the human antibody response against vaccinia virusHuman immune responses to Burkholderia pseudomallei characterized by protein microarray analysis.Effect of the deletion of genes encoding proteins of the extracellular virion form of vaccinia virus on vaccine immunogenicity and protective effectiveness in the mouse model.Smallpox vaccines: targets of protective immunity.Mucosal immunization induces a higher level of lasting neutralizing antibody response in mice by a replication-competent smallpox vaccine: vaccinia Tiantan strainAn epitope conserved in orthopoxvirus A13 envelope protein is the target of neutralizing and protective antibodiesPassive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organsT cell antigen discovery using soluble vaccinia proteome reveals recognition of antigens with both virion and nonvirion association.Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAsStructural and Functional Characterization of Anti-A33 Antibodies Reveal a Potent Cross-Species Orthopoxviruses Neutralizer.Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.Development of a Genus-Specific Antigen Capture ELISA for Orthopoxviruses - Target Selection and Optimized ScreeningUncovering the interplay between CD8, CD4 and antibody responses to complex pathogens.Humoral immunity to smallpox vaccines and monkeypox virus challenge: proteomic assessment and clinical correlations.Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine.Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaquesLinear Epitopes in Vaccinia Virus A27 Are Targets of Protective Antibodies Induced by Vaccination against Smallpox.The Vaccinia Virus H3 Envelope Protein, a Major Target of Neutralizing Antibodies, Exhibits a Glycosyltransferase Fold and Binds UDP-GlucoseVaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complementVaccinia virus entry/fusion complex subunit A28 is a target of neutralizing and protective antibodiesVaccinia virus-specific CD8(+) T-cell responses target a group of epitopes without a strong immunodominance hierarchy in humansThe heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays.A Burkholderia pseudomallei protein microarray reveals serodiagnostic and cross-reactive antigens
P2860
Q27679281-08419A50-39ED-4A0A-B462-BE0E82EF2BDBQ27684713-24EEAC80-CA83-41B3-A765-D26B231F7CC1Q28750496-2EEF2A38-6D47-42C4-8BFC-003175F73FCCQ30994031-644EAE48-ACE9-4E1D-890E-7B610A11DFF2Q33427795-3D7F132F-44DD-4519-8EF3-EBA226CF1267Q33743444-DBF3645B-F3EA-4CE8-A44A-E798BA981205Q33936717-E1CDA832-BB95-4372-A5BB-5101DA4993C1Q33967713-2BA5C601-1DF3-4ABD-922C-39179B0BAF85Q33972574-BB0B0FFE-59AB-4C68-B5C8-B0542B3E53B1Q34023265-81674A84-B659-475E-B749-89B540308EABQ34039477-4FD7EA18-18A6-4074-B622-86210E97A133Q34085985-26904379-8504-47E8-A462-93D6BA36CAE2Q34419934-055E5F37-7AB2-426C-8AA5-7264A62218FCQ34469836-8BDD44D9-AC2B-42E7-B7D6-A20CEA8716F4Q34495128-57FAECA3-BA71-4FA2-AC1F-9B1EEFD10A44Q34529713-83174EC0-8963-498E-9E2E-72F5C500E6F9Q34743375-F5998770-BE93-474F-BF4B-2821B0C64FD5Q34779016-68AF53B9-0360-4640-8C0F-2217338D7D60Q34780607-5BCA0417-E36B-403B-9AD4-3C222FDA758BQ35099487-2A1B2653-7728-4819-86B5-B3FF3878862FQ35186318-980132E0-835A-4599-B241-8457484DCF30Q35192889-A2257FBE-4DC6-470D-9389-7CDCBB7A2341Q35206861-A4460746-F297-4416-B7CE-58864B22541BQ35339702-7DCB1FA5-8BC7-41E2-A3F2-20F75B47CBFCQ35557123-3902FEB5-9630-4FBF-A637-F3FBAD5CAAA4Q35634159-5C3E7D07-6E37-4736-AF77-43EC7EBC8633Q35760869-22BA039D-4A45-4877-8FC2-7F2A364C8F4BQ35826728-009842C5-3783-48FF-AA1F-CC0770C448A3Q35941208-6AB821FC-4858-4ADD-8AA2-F59A5C719A5AQ35998125-F16C793A-F8F1-4244-9CCD-3884B7765985Q36559636-461F9965-6134-4C81-86E0-72B70B42CFF3Q36559797-8FBA575B-AA66-4007-811E-ACEEA73DF5E7Q36756690-AA2FF91C-8C53-4082-9B15-6FE501C54D12Q36811880-469B2B83-DAF3-42C0-ADEB-B35B9A31909AQ36878858-16969E00-B22F-4D9C-8838-3AEE121342A2Q37051617-39FF4303-209F-4A4D-A3BD-127035B8951BQ37066691-EE1B75AF-8C2A-4C7F-87AC-B600CBE3B288Q37089515-4381E71D-6ADC-424B-B846-283DF94C3442Q37169163-DA6F759F-CDF6-4EA5-B150-F95B9DA552C8Q37278865-2BC10937-E626-42EF-B607-39E436F80936
P2860
Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Redundancy and plasticity of n ...... ponse to the smallpox vaccine.
@ast
Redundancy and plasticity of n ...... ponse to the smallpox vaccine.
@en
type
label
Redundancy and plasticity of n ...... ponse to the smallpox vaccine.
@ast
Redundancy and plasticity of n ...... ponse to the smallpox vaccine.
@en
prefLabel
Redundancy and plasticity of n ...... ponse to the smallpox vaccine.
@ast
Redundancy and plasticity of n ...... ponse to the smallpox vaccine.
@en
P2093
P2860
P356
P1433
P1476
Redundancy and plasticity of n ...... ponse to the smallpox vaccine.
@en
P2093
D Huw Davies
David N Garboczi
Hua-Poo Su
Julia Hoffmann
Kavita Singh
Megan M McCausland
Philip L Felgner
Shane Crotty
Steven Head
P2860
P304
P356
10.1128/JVI.02244-07
P407
P577
2008-01-30T00:00:00Z